The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Hopkins, Robert B ^a,b   Goeree, Ron ^a,b,c   Pullenayegum, Eleanor ^a,c,d   Adachi, Jonathan D ^e   Papaioannou, Alexandra ^e   Xie, Feng ^a,b,c   Thabane, Lehana ^a,c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b Programs for Assessment of Technology in Health Research Institute   (Canada)

^c CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^d ST JOSEPH S HEALTH CENTRE   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BAYES THEOREM; DRUG EFFICACY; EFFECT SIZE; FRACTURE; HIP FRACTURE; HUMAN; META ANALYSIS; NONVERTEBRAL FRACTURE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; VERTEBRA FRACTURE; WRIST FRACTURE; FEMALE; FRAGILITY FRACTURE; REVIEW; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80053344658     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-209     Document Type: Article

References (58)

1. Osteoporosis Facts and Statistics. http://www.osteoporosis.ca/index.php/ ci-id/8867/la-id/1.htm
2. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E, Osteoporos Int 2001 12 271 278 10.1007/s001980170116 11420776 (Pubitemid 34912733)
3. Long-term risk of incident vertebral fractures. Cauley JA, Hochberg MC, Lui LY, Palermo L, Ensrud KE, Hillier TA, Nevitt MC, Cummings SR, JAMA 2007 298 2761 2767 10.1001/jama.298.23.2761 18165669 (Pubitemid 350294299)
4. Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis. Bilezikian JP, American Journal of Medicine 122(2 SUPPL)()(pp S14-S21), 2009 Date of Publication: 2009 2009 14 S21
5. EMEA guidelines for trials in osteoporosis: design implications. Boers M, Neth J Med 2002 60 310 314 12481877 (Pubitemid 39089337)
6. The ethics of placebo in studies with fracture end points in osteoporosis. Stein CM, Ray WA, N Engl J Med 2010 363 1367 1370 10.1056/NEJMsb1006120 20879888
7. Placebo-controlled trials in osteoporosis - proceeding with caution. Rosen CJ, Khosla S, N Engl J Med 2010 363 1365 1367 10.1056/NEJMsb1002227 20879887
8. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council, Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans 2010
9. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Song F, Altman DG, Glenny AM, Deeks JJ, BMJ 2003 326 472 10.1136/bmj.326.7387.472 12609941
10. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Bucher HC, Guyatt GH, Griffith LE, Walter SD, J Clin Epidemiol 1997 50 683 691 10.1016/S0895-4356(97)00049-8 9250266 (Pubitemid 27341818)
11. A Bayesian method for synthesizing evidence. The Confidence Profile Method. Eddy DM, Hasselblad V, Shachter R, Int J Technol Assess Health Care 1990 6 31 55 10.1017/S0266462300008928 2361818 (Pubitemid 20287160)
12. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Jansen JP, Bergman GJ, Huels J, Olson M, Curr Med Res Opin 2009 25 1861 1868 10.1185/03007990903035281 19530978
13. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Jansen JP, Bergman GJ, Huels J, Olson M, Semin Arthritis Rheum 2011 40 275 284 10.1016/j.semarthrit.2010.06.001 20828791
14. Reference Manager, Version 11 for Windows. Thomson ResearchSoft. Carlsbad, CA, USA Carlsbad, CA, USA, Thomson ResearchSoft 2009
15. The Bayesian inference Using Gibbs Sampling(BUGS) Project: WinBUGS. http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml
16. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA, J Clin Epidemiol 2005 58 261 268 10.1016/j.jclinepi.2004.08. 010 15718115 (Pubitemid 40249468)
17. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Caldwell DM, Ades AE, Higgins JP, BMJ 2005 331 897 900 10.1136/bmj.331.7521.897 16223826 (Pubitemid 41502718)
18. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Edwards SJ, Clarke MJ, Wordsworth S, Borrill J, Int J Clin Pract 2009 63 841 854 10.1111/j.1742-1241.2009.02072.x 19490195
19. Indirect comparisons of competing interventions. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ, Health Technol Assess 2005 9 1 iv 16303099
20. Combination of direct and indirect evidence in mixed treatment comparisons. Lu G, Ades AE, Stat Med 2004 23 3105 3124 10.1002/sim.1875 15449338 (Pubitemid 39334902)
21. Review Manager (RevMan) [Computer program] Version 5.0. Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration 2008
22. Higgins JP, Green S, editors, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 The Cochrane Collaboration 2009
23. Indirect treatment comparison [computer program]. Version 1.0. Wells G, Sultan S, Chen L, Khan M, Coyle D, Wells GA, Sultan SA, Chen L, Khan M, Coyle D, Ottawa, Canadian Agency for Drugs and Technologies in Health 2009
24. The Canadian Agency for Drugs and Technologies in Health (CADTH). http://www.cadth.ca/index.php/en/home
25. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Moher D, Liberati A, Tetzlaff J, Altman DG, Ann Intern Med 2009 151 264 9 W64 19622511
26. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, Stych B, Melton ME, Arch Intern Med 2003 163 789 794 10.1001/archinte.163.7.789 12695269 (Pubitemid 36438050)
27. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, et al. Lancet 1996 348 1535 1541 10.1016/S0140-6736(96)07088-2 8950879 (Pubitemid 26411651)
28. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, et al. JAMA 1998 280 2077 2082 10.1001/jama.280.24.2077 9875874 (Pubitemid 29014065)
29. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB, J Bone Miner Res 1998 13 1431 1438 10.1359/jbmr.1998.13.9.1431 9738515 (Pubitemid 28418909)
30. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, N Engl J Med 1995 333 1437 1443 10.1056/NEJM199511303332201 7477143
31. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, et al. Osteoporos Int 1999 9 461 468 10.1007/PL00004171 10550467 (Pubitemid 29231740)
32. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, et al. N Engl J Med 2009 361 756 765 10.1056/NEJMoa0809493 19671655
33. The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. Lyritis GP, Tsakalakos N, Paspati I, Skarantavos G, Galanos A, Androulakis C, Clin Rheumatol 1997 16 354 360 10.1007/BF02242451 9259248 (Pubitemid 27319958)
34. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R, J Clin Endocrinol Metab 1997 82 2784 2791 10.1210/jc.82.9.2784 9284696 (Pubitemid 27385624)
35. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K, Osteoporos Int 1997 7 52 58 9102064 (Pubitemid 27077788)
36. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. Pacifici R, McMurtry C, Vered I, Rupich R, Avioli LV, J Clin Endocrinol Metab 1988 66 747 753 10.1210/jcem-66-4-747 3126214
37. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Pouilles JM, Tremollieres F, Roux C, Sebert JL, Alexandre C, Goldberg D, Treves R, Khalifa P, Duntze P, Horlait S, et al. Osteoporos Int 1997 7 213 218 9205633 (Pubitemid 27226352)
38. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH, N Engl J Med 1990 322 1265 1271 10.1056/NEJM199005033221803 2109197 (Pubitemid 20152489)
39. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, et al. N Engl J Med 1990 323 73 79 10.1056/NEJM199007123230201 2113611 (Pubitemid 20221642)
40. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Wimalawansa SJ, Am J Med 1998 104 219 226 10.1016/S0002-9343(98) 00029-1 9552083 (Pubitemid 28163165)
41. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD, Bone 2004 34 881 889 10.1016/j.bone.2004.01.007 15121020 (Pubitemid 38581134)
42. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, et al. J Bone Miner Res 2004 19 1241 1249 10.1359/JBMR.040325 15231010 (Pubitemid 41094364)
43. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Ravn P, Neugebauer G, Christiansen C, Bone 2002 30 320 324 10.1016/S8756-3282(01)00665-2 11792604 (Pubitemid 34044334)
44. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Recker R, Stakkestad JA, Chesnut CH, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD, Bone 2004 34 890 899 10.1016/j.bone.2004.01. 008 15121021 (Pubitemid 38581135)
45. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, et al. JAMA 1999 282 637 645 10.1001/jama.282.7.637 10517716 (Pubitemid 29384151)
46. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY, J Clin Endocrinol Metab 2000 85 1895 1900 10.1210/jc.85.5.1895 10843171 (Pubitemid 32269295)
47. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, et al. JAMA 1999 282 1344 1352 10.1001/jama.282.14.1344 10527181 (Pubitemid 29483192)
48. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, Ernst TF, Wenderoth D, Climacteric 2005 8 251 262 10.1080/13697130500118126 16390757 (Pubitemid 41224437)
49. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, et al. N Engl J Med 2001 344 333 340 10.1056/NEJM200102013440503 11172164 (Pubitemid 32107641)
50. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr, J Clin Endocrinol Metab 1998 83 396 402 10.1210/jc.83.2.396 9467547 (Pubitemid 28496512)
51. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, et al. Osteoporos Int 2000 11 83 91 10.1007/s001980050010 10663363 (Pubitemid 30099515)
52. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, et al. N Engl J Med 2004 350 459 468 10.1056/NEJMoa022436 14749454 (Pubitemid 38133766)
53. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Reginster JY, Felsenberg D, Boonen S, ez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, et al. Arthritis Rheum 2008 58 1687 1695 10.1002/art.23461 18512789 (Pubitemid 351847521)
54. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, et al. N Engl J Med 2001 344 1434 1441 10.1056/NEJM200105103441904 11346808 (Pubitemid 32402100)
55. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, et al. N Engl J Med 2007 356 1809 1822 10.1056/NEJMoa067312 17476007 (Pubitemid 46698462)
56. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P, J Clin Endocrinol Metab 2007 92 1415 1423 10.1210/jc.2006-1404 17264183 (Pubitemid 46556419)
57. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Nixon R, Bansback N, Brennan A, Rheumatology (Oxford) 2007 46 1140 1147 10.1093/rheumatology/kem072 (Pubitemid 47050618)
58. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. Salanti G, Marinho V, Higgins JP, J Clin Epidemiol 2009 62 857 864 10.1016/j.jclinepi.2008.10.001 19157778